Homepage Top Section2

Imbruvica is already approved in Europe for chronic lymphocytic leukaemia as a monotherapy or in combination with obinutuzumab in patients who were previously untreated for their condition. The

Via its subsidiary, Merck has completed the cash tender offer to acquire all the outstanding shares of ArQule at a purchase price of $20 per share. Merck said

As per the terms of the deal, the Japanese pharma company and Adaptimmune will select up to three targets for their collaboration and will co-develop T-cell therapy candidates

Ovaprene is Daré’s investigational hormone-free monthly vaginal contraceptive, which is under clinical development to prevent pregnancy. Under the exclusive licence agreement, Bayer will commercialise Ovaprene after it is

SM-88 is one of the cancer metabolism-based therapies (CMBTs) that are being developed by Tyme Technologies. According to the company, CMBTs are investigational compounds that can potentially disrupt

Reported to be the world’s largest independent funder of cancer research, Cancer Research UK will provide funding for the exploratory development of Bicycle’s BT7401 candidate through a phase

As per the deal announced in December 2019, Charles River Laboratories offered to buy HemaCare for $25.40 per share. The California-based company, which will now operate under Charles

Under the terms of the transaction agreement, GSK has received an upfront payment of €308m ($345m) and Bavarian Nordic is expected to pay a total of up to

The US regulator has approved Lynparza as a maintenance treatment for adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma (pancreatic cancer) whose disease